此外，康希诺生物拟8月29日举行董事会会议审批中期业绩。公司一季度业绩显示，营业收入1.14亿元人民币，同比增加13.65%；亏损1.7亿元，同比扩大约21.43%。值得注意的是，2023年起，康希诺生物销售重点由新冠疫苗转向流脑疫苗。Cansinobio (06185) fell more than 6% in the final trading, as of the press time, down 6.16%, at HK$16.44, with a turnover of HK$26.9038 million.
According to the CITIC Securities Journal app, Cansinobio (06185) fell more than 6% in the final trading, as of the press time, down 6.16%, at HK$16.44, with a turnover of HK$26.9038 million.
On the news front, on August 16, the Hang Seng Index Company announced the latest interim review results, in which cansinobio was removed from the Hang Seng Composite Smallcap Index, and the change will take effect on September 9. Anxin International stated that the company is A + H, so it can retain its Hong Kong Stock Connect eligibility.
In addition, cansinobio plans to hold a board of directors meeting to approve its mid-term performance on August 29. The company's Q1 performance showed revenue of RMB 0.114 billion, a year-on-year increase of 13.65%, and a loss of RMB 0.17 billion, an increase of about 21.43% year-on-year. It is worth noting that starting from 2023, cansinobio's sales focus will shift from COVID-19 vaccines to meningococcal vaccines.
